{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:22:01Z","timestamp":1779085321890,"version":"3.51.4"},"reference-count":112,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.amjmed.2023.06.013","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T15:13:01Z","timestamp":1687792381000},"page":"1147-1159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Medical Management of Coronary Artery Disease in Patients with Chronic Kidney Disease"],"prefix":"10.1016","volume":"136","author":[{"given":"Jitae A.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seulgi E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"El Hachem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafeez Ul Hassan","family":"Virk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahboob","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samin","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"House","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chayakrit","family":"Krittanawong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.amjmed.2023.06.013_bib0001","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease: JACC state-of-the-art review","volume":"74","author":"Sarnak Mark","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9844","key":"10.1016\/j.amjmed.2023.06.013_bib0002","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","article-title":"Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study","volume":"380","author":"Tonelli","year":"2012","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.amjmed.2023.06.013_bib0003","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa1915925","article-title":"Management of coronary disease in patients with advanced kidney disease","volume":"382","author":"Bangalore","year":"2020","journal-title":"N Engl J Med"},{"issue":"9784","key":"10.1016\/j.amjmed.2023.06.013_bib0004","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.amjmed.2023.06.013_bib0005","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjmed.2023.06.013_bib0006","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.amjmed.2023.06.013_bib0007","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.amjmed.2023.06.013_bib0008","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2023.06.013_bib0009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.amjmed.2023.06.013_bib0010","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.amjmed.2023.06.013_bib0011","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjmed.2023.06.013_bib0012","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1161\/CIRCULATIONAHA.118.032078","article-title":"P2Y12-ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes","volume":"138","author":"Bonello","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0013","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2215\/CJN.04100321","article-title":"Platelet abnormalities in CKD and their implications for antiplatelet therapy","volume":"17","author":"Baaten","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"25","key":"10.1016\/j.amjmed.2023.06.013_bib0014","first-page":"e344","article-title":"2014 AHA\/ACC Guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.amjmed.2023.06.013_bib0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0016","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2022.2154330","article-title":"Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum","volume":"34","author":"Varian","year":"2023","journal-title":"Platelets"},{"issue":"2","key":"10.1016\/j.amjmed.2023.06.013_bib0017","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1067\/mhj.2002.125513","article-title":"Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease","volume":"144","author":"McCullough","year":"2002","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.amjmed.2023.06.013_bib0018","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0735-1097(03)00572-2","article-title":"Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction","volume":"42","author":"Berger","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.amjmed.2023.06.013_bib0019","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2011.08.051","article-title":"Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease","volume":"58","author":"Basra","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.amjmed.2023.06.013_bib0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","volume":"121","author":"Fox","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.amjmed.2023.06.013_bib0021","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/jth.13211","article-title":"Antiplatelet effects of aspirin in chronic kidney disease patients","volume":"14","author":"Polzin","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.amjmed.2023.06.013_bib0022","doi-asserted-by":"crossref","first-page":"563","DOI":"10.7326\/0003-4819-137-7-200210010-00007","article-title":"Acute myocardial infarction and renal dysfunction: a high-risk combination","volume":"137","author":"Wright","year":"2002","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.amjmed.2023.06.013_bib0023","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.ajkd.2005.07.043","article-title":"Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia","volume":"46","author":"Keough-Ryan","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.amjmed.2023.06.013_bib0024","first-page":"115","article-title":"Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes","volume":"22","author":"Yan","year":"2006","journal-title":"Can J Cardiol"},{"issue":"2","key":"10.1016\/j.amjmed.2023.06.013_bib0025","article-title":"Antiplatelet agents for chronic kidney disease","volume":"2","author":"Natale","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0026","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13063-022-06132-z","volume":"23","author":"Gallagher","year":"2022","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.amjmed.2023.06.013_bib0027","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-018-6802-1","article-title":"Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study)","volume":"32","author":"Goicoechea","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10","key":"10.1016\/j.amjmed.2023.06.013_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012236","article-title":"Safety of dual-antiplatelet therapy after myocardial infarction among patients with chronic kidney disease","volume":"8","author":"Rymer","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.amjmed.2023.06.013_bib0029","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00380-022-02029-8","article-title":"Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT)","volume":"37","author":"Graham","year":"2022","journal-title":"Heart Vessels"},{"issue":"3","key":"10.1016\/j.amjmed.2023.06.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.006144","volume":"11","author":"Baber","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.amjmed.2023.06.013_bib0031","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.amjmed.2023.06.013_bib0032","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.amjmed.2023.06.013_bib0033","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.amjmed.2023.06.013_bib0034","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/bcp.13436","article-title":"Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease","volume":"84","author":"Wang","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"20","key":"10.1016\/j.amjmed.2023.06.013_bib0036","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jcin.2017.02.047","article-title":"Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the PROMETHEUS study","volume":"10","author":"Baber","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.amjmed.2023.06.013_bib0037","first-page":"443","article-title":"Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: insights from the TRILOGY ACS Trial","volume":"5","author":"Melloni","year":"2016","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"16","key":"10.1016\/j.amjmed.2023.06.013_bib0038","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2023.06.013_bib0039","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/ATVBAHA.115.306528","article-title":"Platelet p2y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model","volume":"35","author":"Thomas","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.amjmed.2023.06.013_bib0040","first-page":"1606","article-title":"Effect of clopidogrel vs ticagrelor on platelet aggregation and inflammation markers after percutaneous coronary intervention for ST-elevation myocardial infarction","volume":"34","author":"Jiang","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjmed.2023.06.013_bib0041","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ahj.2020.04.013","article-title":"TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: the TROUPER trial","volume":"225","author":"Laine","year":"2020","journal-title":"Am Heart J"},{"issue":"19","key":"10.1016\/j.amjmed.2023.06.013_bib0042","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/heartjnl-2017-312436","article-title":"Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function","volume":"104","author":"Edfors","year":"2018","journal-title":"Heart"},{"issue":"21","key":"10.1016\/j.amjmed.2023.06.013_bib0043","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"issue":"45","key":"10.1016\/j.amjmed.2023.06.013_bib0044","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1093\/eurheartj\/ehab533","article-title":"Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD","volume":"42","author":"Stefanini","year":"2021","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.amjmed.2023.06.013_bib0045","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00392-019-01586-9","article-title":"Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial","volume":"109","author":"Tomaniak","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjmed.2023.06.013_bib0046","doi-asserted-by":"crossref","first-page":"i4801","DOI":"10.1136\/bmj.i4801","article-title":"\u03b2 blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study","volume":"354","author":"Puymirat","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.amjmed.2023.06.013_bib0047","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2019.04.067","article-title":"The evolution of \u03b2-blockers in coronary artery disease and heart failure (part 1\/5)","volume":"74","author":"Joseph","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.amjmed.2023.06.013_bib0048","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial invasive or conservative strategy for stable coronary disease","volume":"382","author":"Maron","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.amjmed.2023.06.013_bib0049","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.amjmed.2023.06.013_bib0050","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.ASN.0000113320.57127.B9","article-title":"Sympathetic hyperactivity in chronic renal failure: a wake-up call","volume":"15","author":"Koomans","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.amjmed.2023.06.013_bib0051","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1093\/ndt\/gfm950","article-title":"Beta-blockers for coronary heart disease in chronic kidney disease","volume":"23","author":"Chonchol","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.amjmed.2023.06.013_bib0052","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/CIR.0000000000000183","article-title":"Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome","volume":"131","author":"Washam","year":"2015","journal-title":"Circulation"},{"issue":"9146","key":"10.1016\/j.amjmed.2023.06.013_bib0053","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.amjmed.2023.06.013_bib0054","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurjhf\/hfq038","article-title":"Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial","volume":"12","author":"Castagno","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/CIRCHEARTFAILURE.109.932558","article-title":"Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease","volume":"4","author":"Wali","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"23","key":"10.1016\/j.amjmed.2023.06.013_bib0056","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.jacc.2019.09.059","article-title":"Impact of renal impairment on beta-blocker efficacy in patients with heart failure","volume":"74","author":"Kotecha","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.amjmed.2023.06.013_bib0057","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.amjmed.2023.06.013_bib0058","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/sj.ki.5001835","article-title":"Beta blockers in the management of chronic kidney disease","volume":"70","author":"Bakris","year":"2006","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.amjmed.2023.06.013_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100460","article-title":"\u03b2-Blocker use and cardiovascular outcomes in hemodialysis: a systematic review","volume":"4","author":"Tella","year":"2022","journal-title":"Kidney Med"},{"issue":"18","key":"10.1016\/j.amjmed.2023.06.013_bib0060","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0061","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ki.2013.444","article-title":"Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward","volume":"85","author":"Levin","year":"2014","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.amjmed.2023.06.013_bib0062","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0063","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCULATIONAHA.105.592733","article-title":"Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial","volume":"114","author":"Solomon","year":"2006","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.amjmed.2023.06.013_bib0064","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.amjmed.2005.08.057","article-title":"Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes","volume":"119","author":"Han","year":"2006","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2023.06.013_bib0065","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0066","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.amjmed.2023.06.013_bib0067","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.amjmed.2023.06.013_bib0068","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026407","article-title":"Sacubitril\/valsartan in patients with heart failure and concomitant end-stage kidney disease","volume":"11","author":"Niu","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.amjmed.2023.06.013_bib0069","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"20","key":"10.1016\/j.amjmed.2023.06.013_bib0070","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor\u2013neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjmed.2023.06.013_bib0071","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.amjmed.2023.06.013_bib0072","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjmed.2023.06.013_bib0073","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ahj.2020.10.055","article-title":"Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease","volume":"231","author":"Shavadia","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2023.06.013_bib0074","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.09.018","article-title":"Moderate to high intensity statin in dialysis patients after acute myocardial infarction: a national cohort study in Asia","volume":"267","author":"Chung","year":"2017","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.amjmed.2023.06.013_bib0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.29706","article-title":"Association of statin therapy with major adverse cardiovascular and limb outcomes in patients with end-stage kidney disease and peripheral artery disease receiving maintenance dialysis","volume":"5","author":"Lo","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.amjmed.2023.06.013_bib0076","article-title":"HMG CoA reductase inhibitors (statins) for dialysis patients","author":"Palmer","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.amjmed.2023.06.013_bib0077","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1753944713513222","article-title":"Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients","volume":"7","author":"Suzuki","year":"2013","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"18","key":"10.1016\/j.amjmed.2023.06.013_bib0078","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.amjmed.2023.06.013_bib0079","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"42","key":"10.1016\/j.amjmed.2023.06.013_bib0080","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Tu\u00f1\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.amjmed.2023.06.013_bib0081","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.amjmed.2023.06.013_bib0082","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003196","article-title":"Ranolazine: a contemporary review","volume":"5","author":"Rayner-Hartley","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0083","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/0886022X.2019.1585371","article-title":"Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis","volume":"41","author":"Scoville","year":"2019","journal-title":"Ren Fail"},{"issue":"20","key":"10.1016\/j.amjmed.2023.06.013_bib0084","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","article-title":"Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions","volume":"113","author":"Chaitman","year":"2006","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0085","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/0886022X.2019.1707098","article-title":"Acquired long QT syndrome in chronic kidney disease patients","volume":"42","author":"Liu","year":"2020","journal-title":"Ren Fail"},{"issue":"15","key":"10.1016\/j.amjmed.2023.06.013_bib0086","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.amjmed.2023.06.013_bib0087","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2023.06.013_bib0088","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjmed.2023.06.013_bib0089","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/M22-2904","article-title":"Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update","volume":"176","author":"Navaneethan","year":"2023","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1016\/j.amjmed.2023.06.013_bib0090","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2023.06.013_bib0091","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","article-title":"Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.amjmed.2023.06.013_bib0092","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjmed.2023.06.013_bib0093","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.amjmed.2023.06.013_bib0094","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.kisu.2021.11.008","article-title":"Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists\u2013unmet needs and underserved patient cohorts","volume":"12","author":"Epstein","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"issue":"5S","key":"10.1016\/j.amjmed.2023.06.013_bib0096","first-page":"S1","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.amjmed.2023.06.013_bib0097","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.amjmed.2023.06.013_bib0098","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.amjmed.2023.06.013_bib0099","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.amjmed.2023.06.013_bib0100","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/ckj\/sfac069","article-title":"GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art","volume":"15","author":"Granata","year":"2022","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.amjmed.2023.06.013_bib0101","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jacc.2018.05.027","article-title":"Coronary calcium score and cardiovascular risk","volume":"72","author":"Greenland","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.amjmed.2023.06.013_bib0102","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCRESAHA.123.321760","article-title":"Cardiovascular calcification heterogeneity in chronic kidney disease","volume":"132","author":"Hutcheson","year":"2023","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.amjmed.2023.06.013_bib0103","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamacardio.2017.0363","article-title":"Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease","volume":"2","author":"Chen","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2023.06.013_bib0104","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/0886022X.2019.1595646","article-title":"Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"41","author":"Wang","year":"2019","journal-title":"Ren Fail"},{"issue":"4","key":"10.1016\/j.amjmed.2023.06.013_bib0105","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jacbts.2020.02.002","article-title":"Targeting vascular calcification in chronic kidney disease","volume":"5","author":"Nelson","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"10.1016\/j.amjmed.2023.06.013_bib0106","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2014.10.005","article-title":"KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD","volume":"65","author":"Sarnak","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"9374","key":"10.1016\/j.amjmed.2023.06.013_bib0107","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.amjmed.2023.06.013_bib0108","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"issue":"suppl 7","key":"10.1016\/j.amjmed.2023.06.013_bib0109","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"issue":"suppl 3","key":"10.1016\/j.amjmed.2023.06.013_bib0110","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.amjmed.2023.06.013_bib0111","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/j.1600-6143.2009.02696.x","article-title":"Use of cardioprotective medications in kidney transplant recipients","volume":"9","author":"Gaston","year":"2009","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.amjmed.2023.06.013_bib0112","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1111\/j.1399-0012.2010.01297.x","article-title":"Cardioprotective medication use after renal transplantation","volume":"24","author":"Dawson","year":"2010","journal-title":"Clin Transplant"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323004072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323004072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:32:11Z","timestamp":1757583131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934323004072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":112,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0002934323004072"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.06.013","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Management of Coronary Artery Disease in Patients with Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}